{
    "symbol": "EVGN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-10 00:11:02",
    "content": " For example, Evogene is using forward-looking statements in this call when it discusses its expected path to value creation, including potential fundraisings at the subsidiary level, its and its subsidiaries, expected trials and their expected results, studies, product advancements, commercialization, launches, pipelines, milestones, potential collaborations and other plans for 2023 and beyond, expected burn rate, the potential advantages of its technology and its anticipated entry into new fields of activity. It\u00e2\u0080\u0099s important to me to emphasize that Evogene is actively looking to increase shareholder value by entering into various business relationship with leading multinational companies for product development using our engines, generating revenue by commercializing and selling products, meeting all its milestones, including those under various collaboration agreements, raising external funds at the subsidiary level that demonstrate their value and working hard to provide shareholders with a greater understanding of our business and subsidiaries achievements. For 2022, our consolidated cash burn usage was $28.5 million or approximately $20 million, excluding Lavie Bio. For 2022, our consolidated cash burn usage was $28.5 million or approximately $20 million, excluding Lavie Bio. The main contributors to R&D expenses were Lavie Bio\u00e2\u0080\u0099s activities supporting the production and commercialization of its inoculant product, Thrivus, Evogene\u00e2\u0080\u0099s ongoing development of its technology engine and Biomica\u00e2\u0080\u0099s microbiome-based therapeutics development efforts."
}